Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM ...

INmune Bio’s INMB stock price rose 12.2% on Wednesday after management announced that it has dosed the first patient in a phase II study with XPro1595 (XPro), its investigational candidate for ...

Moss stated, "For our CORDStrom program, we have a number of significant events in front of us. In Q4, we'll present additional data from the trial. In mid-'26, we expect to file a marketing ...

Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational ...

OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product, Vivo, a ...

Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE ...

Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval ...

The company is targeting the release of top-line data for the XPro Phase 2 Alzheimer's trial in June, with specific emphasis on cognitive and functional endpoints. Plans to complete CORDStrom's BLA ...

The company’s reliance on future clinical trial results introduces significant uncertainty regarding the potential success of its drug candidates, highlighting risks that may deter investors. The ...

XPro™ is a next-generation, selective soluble TNF inhibitor designed to selectively neutralize soluble TNF (sTNF) and restore ...

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience ...

INmune Bio (INMB) announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, “XPro1595, a Selective Soluble TNF Neutralizer, in Early ...